Open access
Aug 2026
Evaluating Immunotherapy Outcomes in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer (KCSG LU23-15).
The clinical benefit of adding atezolizumab appears attenuated in ES-SCLC patients age 75 years or older, supporting careful selection and age-adapted treatment strategies.
Yun-Gyoo Lee, Tae-Hwan Kim, Du-Young Kang et al.
· Cancer research and treatmen... · 0 citations